DexCom, Inc. (DXCM)
|Net Income (ttm)||231.10M|
|Trading Day||January 15|
|Day's Range||347.59 - 356.75|
|52-Week Range||191.16 - 451.79|
The stock market's benchmark index is packed with big-time value.
DexCom (DXCM) posts solid fourth-quarter and full-year 2020 revenue data on the back of resilience shown in the face of the COVID-19 induced challenges.
Teladoc (TDOC) and Dexcom jointly provide solutions for patients with Type 2 diabetes, a common lifestyle-induced malady.
These two providers of diabetes-related products and services have yet to scratch the surface of their potential.
Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2020 and Provides Initial 2021 Outlook
SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2020 and Provides Initial 2021 Outlook
DexCom (DXCM) closed the most recent trading day at $388.09, moving +0.24% from the previous trading session.
SAN DIEGO--(BUSINESS WIRE)--Dexcom to Present at 39th Annual J.P. Morgan Healthcare Conference
These stocks can handle whatever the new year has in store.
The highflying Nasdaq 100 is hiding some serious value in plain sight.
Businesses in these fast-growing trends can shine in a young bull market.
In the latest trading session, DexCom (DXCM) closed at $355.02, marking a -0.27% move from the previous day.
DexCom is an attractive company riding a long-term secular trend in the growth of chronic care management. Stock has performed well this year and is trading at the high range of historical ave...
DexCom (DXCM) closed at $358.57 in the latest trading session, marking a +0.18% move from the prior day.
This healthcare technology company is disrupting the diabetes market with innovative technologies that patients love.
DexCom CEO: We're more bullish about the business than we've ever been
DexCom CEO Kevin Sayer reaffirms his long-term outlook for the diabetes management company, forecasting growth as high as 20% through 2025.
Investors have a few questions as the company faces increasing competition.
These companies have growth opportunities that will last long after the COVID vaccine gets life back to normal.
These stocks could make you a fortune over the next decade.
Medical device which has for long taken tiny steps toward IoMT is now going all out to make the most of the advancements in this space amid the pandemic.
Probably not, but it'll still beat the market.
Biotech stocks simply can't match these reliable returns.
These two companies are battling for market share of continuous glucose monitoring devices for diabetes, with each coming out with new models soon.
G7 could change the valuation dramatically. It is a risky play, especially in the short term.
Instead of investing in the company that would have made you a millionaire years ago, seek out the ones that have the potential from here.
SAN DIEGO--(BUSINESS WIRE)--Dexcom Announces Upcoming Virtual Conference Presentations
These stocks have beaten the odds in 2020 and can weather future storms.
With the disruption that the coronavirus caused us, the dependency on tech-based solutions makes these IoT stocks very relevant. The post 7 IoT Stocks That Are Banking on a Connected Future ap...
An analyst downgrade and marketwide turbulence weighed on the medical device maker's shares last month.
This medical device manufacturer has shown incredible momentum.
A Relative Strength Rating upgrade for Dexcom shows improving technical performance. The post Stock Upgrades: Dexcom Shows Rising Relative Strength appeared first on Investor's Business Daily.
IOT stocks represent companies on the cusp of a new paradigm where everyday objects connect to the internet. Here are seven that stand out.
If you're interested in high-growth biotech stocks with superior fundamentals, here are which ones to consider, and which ones to skip. The post Which Biotech Stocks Are a Buy on Earnings?
SAN DIEGO--(BUSINESS WIRE)--Dexcom to Host Investor Day on December 9, 2020
DexCom's (DXCM) third-quarter results benefit from solid segmental performance.
The diabetes care technology provider also again raised its full-year guidance.
DexCom, Inc. (DXCM) CEO Kevin Sayer on Q3 2020 Results - Earnings Call Transcript
DexCom (DXCM) delivered earnings and revenue surprises of 46.88% and 4.96%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of DexCom (NASDAQ:DXCM) rose 1.15% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 44.62% over the past year to $0.94, which ...
SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Third Quarter 2020 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Dexcom Announces Retirement of Rick Doubleday and Pre-Announcement of Third Quarter 2020 Revenue
These fast-growing medical device companies could outperform the S&P 500 over the next several years.
DexCom (DXCM) closed at $387.84 in the latest trading session, marking a -1.17% move from the prior day.
DexCom's (DXCM) third-quarter results are likely to reflect rising global awareness of its real-time CGM.
DexCom (DXCM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DexCom (DXCM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
These two healthcare companies have much more room to grow than the tech giant does.
SAN DIEGO--(BUSINESS WIRE)--Dexcom Appoints Kyle Malady to Board of Directors
In the latest trading session, DexCom (DXCM) closed at $387.50, marking a -1.6% move from the previous day.
INDIANAPOLIS and SAN DIEGO, Oct. 7, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and DexCom, Inc. (NASDAQ: DXCM) announced today a joint program for U.S. healthcare providers (HCPs) ...
An analyst's downgrade is weighing on the medical device stock.
DexCom, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring sys... [Read more...]
Diagnostics & Research
|IPO Date |
Apr 14, 2005
|Stock Exchange |
|Ticker Symbol |
According to 21 analysts, the average rating for DexCom stock is "Buy." The 12-month stock price forecast is 460.22, which is an increase of 29.93% from the latest price.